Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
Paxlovid is the first oral therapy specifically designed to combat Covid-19 to be evaluated in a pediatric clinical study
Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies
Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
Subscribe To Our Newsletter & Stay Updated
